# Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

> **NCT00407758** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 28 (actual)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** enzastaurin hydrochloride

## Key facts

- **NCT ID:** NCT00407758
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2016-08-01
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407758, "Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00407758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*